Figure 1 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study
Real-world study shows tumor fraction from ctDNA predicts clinical benefit from immune checkpoint inhibitors in cancer patients, suggesting potential for improved treatment strategies.
Key Points
Tumor fraction from ctDNA significantly predicts clinical benefit from immune checkpoint inhibitors in various cancers, enhancing personalized medicine approaches.
In analysis from the RADIOHEAD study, specific methylation changes correlated with improved long-term outcomes in patients undergoing immune therapy.
Assessment involved evaluating QC metrics for patient samples to ensure accurate measurement of ctDNA levels and tumor fractions.
Findings may guide treatment decisions and optimize the use of immune checkpoint inhibitors in a real-world cancer population.